Sildenafil in Infants and Children

Larisa Simonca and Robert Tulloh *

Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK;
simonca.larisa12@gmail.com
* Correspondence: Robert.Tulloh@bristol.ac.uk; Tel.: +44-117-342-8856

Abstract: Pulmonary arterial hypertension (PAH) management has been transformed in recent times with the advent of cheap and effective diagnostic tools and therapy. Sildenafil, a phosphodiesterase-V inhibitor, has been at the centre of this treatment, and its success in treating PAH has led to its widespread uptake in adult and paediatric pulmonary hypertension (PH), as a first line treatment choice. This might apply to persistent pulmonary hypertension of the newborn (PPHN) or bronchopulmonary dysplasia, as well as to more complex diseases, such as idiopathic pulmonary hypertension. Although recent data regarding long-term mortality and the repeal of Food and Drug Administration (FDA) approval has complicated the issue, Sildenafil continues to be the major treatment option for paediatric PH for patients in a variety of contexts, and this does not seem likely to change in the foreseeable future. In this review, we provide a summary of pulmonary hypertension in infants and children and the use of Sildenafil for such diseases.

Keywords: pulmonary hypertension; Sildenafil; phosphodiesterase inhibitor

1. Introduction

Pulmonary hypertension (PH) is a chronic pathology with a progressive nature that, without treatment, can cause various complications, such as right-sided heart failure and death [1]. Often screened by means of echocardiography, a mean pulmonary arterial pressure over 25 mm Hg at rest, observed at the catheterization of the right heart, defines this condition [2]. Any child who experiences shortness of breath, who tires easily, or has syncopal episodes, should be suspected of suffering from PH, even in the presence of heart or lung disease. Making the correct diagnosis is important in order to effectively treat and improve the quality of life for such patients. An echocardiogram that shows a tricuspid regurgitation at a peak Doppler velocity exceeding 2.7 m/s [3], a chest radiograph that reveals reduced peripheral pulmonary vascularity, as well as increased central pulmonary arteries and electrocardiographic markers of right ventricular dilatation or hypertrophy, are the essential findings used to suggest PH [2].

There are a large number of aetiologies that can lead to PH, and although nowadays the majority of the risk factors are known, there are still an important number of cases in which the cause has yet to be discovered. In all cases, PH is a result of the increased resistance to blood flow through the lungs, which is sometimes due to the increased volume of pulmonary blood flow. Therefore, any change in either or all of these variables will consequently cause an increase in pulmonary arterial pressure (Table 1) [4].
Table 1. Aspects of pulmonary hypertension (PH).

| Increased Total Pulmonary Arteriolar Resistance | Increased Pulmonary Blood Flow | Congenital Heart Disease |
|-----------------------------------------------|--------------------------------|--------------------------|
| Precapillary Site                              | Postcapillary Site             |                          |
| • Developmental: No treatment appropriate      | • Obstruction of the blood flow beyond pulmonary capillary bed | • Atrial septal defect (ASD) |
| • Pathologic: Requires treatment               | • Pulmonary vein stenosis      | • Ventricular septal defect (VSD) |
|                                                | • Mitral stenosis              | • Persistent ductus arteriosus (PDA) |
|                                                | • Left ventricle dysfunction   | • Aorto-pulmonary window |
|                                                |                                | • Aorto-pulmonary collateral |
| Five groups of conditions have been classified as leading to PH: (1) pulmonary arterial hypertension (PAH); (2) a reaction to left-sided heart disease; (3) illnesses that emerge from either lung diseases or hypoxia; (4) chronic thromboembolism and (5) a grouping for unclear, unknown, multifactorial mechanisms [5].

Because of the severity of PH and its complications, it is suggested that treatment is initiated as soon as possible. Without treatment, the natural evolution of the condition leads to right-sided heart dysfunction, failure and death [6]. Unfortunately, there is currently only limited data on therapeutic options for PH. However, recent studies have now shown promising results for the use of phosphodiesterase type 5 inhibitors (PDE5 inhibitors), of which Sildenafil has emerged as a top potential therapy.

2. Sildenafil Overview

Sildenafil, a PDE5 inhibitor with high selectivity, increases the level of cyclic guanosine monophosphate (cGMP) in the body [7–9]. The accumulation of cGMP then leads to a series of cellular changes that concludes with a decrease in intracellular calcium levels and the relaxation of smooth muscles [10,11]. New studies suggest that Sildenafil also improves right ventricular function, which reduces vascular smooth muscle contraction (VSMC), as well as proliferation by modulating the Rho-associated kinase signalling [12–14]. PDE5 is found in various locations in the body: corpus cavernosum, retina, platelets, smooth muscles of the vascular system and in high levels in the pulmonary circulation [9,15].

Sildenafil was first approved for erectile dysfunction in 1998, but since then, additional uses for this drug have also been found. In 2005, it was approved for PH in adults and consequently an interest in research arose, questioning whether or not it could also be used successfully in infants and children [16]. Today, Sildenafil is considered an encouraging treatment in PH in infants and children, although it is still used off-label with the need for further studies. Therefore, it should only be administered under careful observation of a paediatric cardiologist [17].

2.1. Pharmacokinetics and Pharmacodynamics

The pharmacokinetics of Sildenafil continue to be of interest in different clinical situations and new ways of administration are being pursued. Most of the information that is available today applies to oral administration. However, sublingual administration, in which the first-pass metabolism was partially bypassed, could be a useful alternative, due to the fact that plasma concentration is increased by over 300%, showing that this route of administration has better outcomes compared to enteral administration [18]. Additionally, sublingual administration can cause a notable increase in effective oxygenation compared to intravenous infusion, although further trials are still required [19]. When parenteral administration is necessary due to various conditions, and intravenous (IV) Sildenafil is not available, administration of a solution consisting of Sildenafil and a facility-approved fluid can be considered via a nasogastric tube [20].
2.2. Absorption

The quick absorption, between 0.5–1.5 h, together with the bioavailability for oral administration of Sildenafil (38–41% in adults), makes it a great route of administration due to the good compliance that is shown in patients. Additionally, an increased absorption and bioavailability has been noted when Sildenafil is administrated sublingually [18]. Furthermore, oral administration has significantly lower costs [21], since even though bioavailability of intravenous use is 100%, increased costs are encountered using IV administration.

2.3. Metabolism

Sildenafil is metabolized in the liver, through specific enzymes (CYP3A4 and CYP2C9), and UK-103 320 is released in circulation as the main metabolite, acquiring 50% of Sildenafil’s potency. In newborns, another important factor is the CYP3A7 enzyme, whose levels are the highest after birth and decrease simultaneously with the increase of CYP3A4 and CYP2C9 during the first week of life [22]. This developmental change that occurs in the first few weeks of life might explain the large inter-patient variability of the response to Sildenafil, but this has yet to be concluded and requires further investigation. Either route of administration that is being used, whether oral or intravenous, results in a half-life ranging from 2–4 h, placing Sildenafil into the short-acting drug group that reaches the maximum plasma concentration after 0.5–2.5 h, targeting a 50–400 ng/mL level of plasma concentration [16,21,23]. It is known that the clearance of Sildenafil metabolites increases threefold in the first few days of life and the volume of distribution is fourfold greater than in adults. This leads to a much longer terminal half-life in neonates [24]. This effect on clearance of Sildenafil in neonates in their first week of life also shows the importance of CYP enzyme developmental changes that occur with age in healthy subjects [25,26]. In case of liver or renal associated pathologies, studies have shown a significant decrease in clearance [25], showing much longer time for excretion and consequently lower Sildenafil clearance has been observed in PH patients [27]. This suggests that in those patients with reduced renal function, the starting dose should be reduced in order to allow for effective clearance of both sildenafil and its metabolites.

2.4. Side Effects and Complications

Pulmonary hypertension has been a difficult condition to treat for a long time, most especially in infants and children, where ethical aspects are exceedingly complex and research studies face many restrictions. Since the approval of Sildenafil in adults, specialists have shown an interest in using the drug in infants and children as well. However, there still remains a constant struggle to find the right balance between risks and benefits in Sildenafil treatment.

Considering Sildenafil’s mechanism of action, which decreases pulmonary arterial pressure, concerns have been raised that Sildenafil could cause serious systemic hypotension and severe haemodynamic instability. Indeed, Sildenafil was first considered as an anti-hypertensive agent. To this day, this effect has not been significantly proven, although there are a few case reports that mention moderate hypotension related to Sildenafil treatment. Additionally, the vasodilatation induced by the blockage of PDE5 inhibitors can lead to nasal congestion, as well as flushing, and can also lead to headaches [3].

Another controversial aspect of Sildenafil is its activity on the PDE6 receptors localized in the rod and cone cells of the eye, and whether or not the drug affects the normal development of the visual function of preterm neonates. However, there has been no proven evidence of a direct link between Sildenafil therapy and ocular complications, although photophobia has been observed in some subjects [3,27–29].

Common side effects of Sildenafil treatment are usually non-life-threatening. Upper respiratory tract infections were the most frequent of the adverse reactions to the treatment, followed, in order of frequency, by vomiting, headache, bronchitis, pyrexia, pharyngitis, cough, diarrhoea and
nasopharyngitis (nasal stuffiness) (Table 2) [30]. Severe adverse effects that were treatment-related and that required immediate termination of the treatment, only appeared in five subjects of the double-blind, placebo-controlled Sildenafil in Treatment-Naive Children with Pulmonary Arterial Hypertension (STARTS-1) study and consisted of stridor and ventricular arrhythmias.

Table 2. Most frequent adverse effects to Sildenafil treatment, as seen in the STARTS 1 study.

| Number | Adverse Effect          | Patients Who Developed Adverse Reactions (n = 234) | Percentage |
|--------|-------------------------|---------------------------------------------------|------------|
| 1      | Upper respiratory tract infection | 53                                                 | 22.64%     |
| 2      | Vomiting                | 45                                                 | 19.23%     |
| 3      | Headache                | 44                                                 | 18.80%     |
| 4      | Bronchitis              | 37                                                 | 15.81%     |
| 5      | Pyrexia                 | 36                                                 | 15.38%     |
| 6      | Pharyngitis             | 31                                                 | 13.24%     |
| 7      | Cough                   | 30                                                 | 12.82%     |
| 8      | Diarrhoea               | 27                                                 | 11.53%     |
| 9      | Nasopharyngitis         | 25                                                 | 10.68%     |

2.5. Indications for Sildenafil in Infants and Children

The guidelines of the European Society of Cardiology (ESC) [1] for PH recommend Sildenafil therapy in children, for those aged 1–17 years old. These recommendations state that once diagnosis is confirmed of Group 1 PH (PAH), those children that fit the criteria for World Health Organisation Functional Class (WHO FC) II and III, could benefit from Sildenafil monotherapy three times a day [1]. The intermediate and high-risk forms, that correspond to the WHO FC III and FC IV, should be treated with combinations of endothelin receptor antagonists (such as Bosentan, Macitentan and Ambrisentan) Sildenafil (or other PDE5 inhibitors) and possibly intravenous epoprostenol. If this treatment fails, double or triple sequential combinations are recommended [1].

3. Persistent Pulmonary Hypertension of the Newborn

The use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn (PPHN) is controversial and needs further investigation, mainly due to the high risk of hypotension that was observed in IV administration. Therefore, it is highly recommended that it should be administrated in a slow IV infusion to reduce the occurrence of such hypotension. Sildenafil has been shown to improve arterial oxygenation by 16 mmHg [31] in patients with PPHN, an effect that was observed with or without previous exposure to nitric oxide (NO) [32], which diminishes the risk of mortality. It has also been recognized that weaning of NO during the recovery period is associated with rebound PH, and Sildenafil has been found to ameliorate this rebound that is observed during inhaled nitric oxide (iNO) weaning [33].

3.1. Bronchopulmonary Dysplasia in Infants and Children

Bronchopulmonary dysplasia (BPD) is a chronic lung disease, more frequently seen in premature infants. Prematurity is observed in 10% of all births and BPD is seen in approximately 10% of these, of whom PH is found in 30–45% of these cases [34,35]. About half of those children who have BPD-PH will die as a result. A remaining challenge is to find a treatment that will improve the quality of life and the survival of BPD patients, taking into account that even after treatment with the most commonly used vasodilator agent (oxygen), the mortality is still 50% [36]. Even though NO can serve as an effective therapy, treatment is costly and long-term therapy can be difficult, as it is an inhaled toxic gas.

Some studies have shown that PDE5 inhibitors normalize lung development, decrease right ventricle peak systolic pressure and improve outcomes [37,38]. Sildenafil can be used as a monotherapy in BPD associated with PH, but only with close supervision and in situations that have no other
option. Sometimes there is need for a combination with other drugs, such as NO, endothelin-receptor antagonists and Prostanoids [39]. Currently however, there has yet to be found significant evidence from a randomized controlled trial (RCT) that Sildenafil improves long-term morbidity or mortality from BPD-PH.

3.2. Congenital Diaphragmatic Hernia in Infants and Children

Pulmonary hypertension associated with congenital diaphragmatic hernia (CDH) in infants and children is a challenging condition to treat. Firstly, the enteral administration of Sildenafil is compromised in the majority of cases, mainly because of the delay in feeding and the food intolerance that can occur [19]. Secondly, the use of Sildenafil in PH associated with CDH is still an off-label use (as are many of the paediatric uses) and does not have enough evidence-based data, therefore it is mandatory to further investigate the treatment effects. The drug could have a potential for therapy for PH associated with CDH, as Bialkowski et al. stated that after 72 h of intravenous Sildenafil use, improvements in oxygenation were observed and that the cardiovascular and respiratory functions benefitted from an early phase treatment [19].

3.3. Eisenmenger’s Syndrome in Infants and Children

Eisenmenger’s Syndrome is defined as an untreated septal defect that leads to increased pulmonary vascular resistance (PVR) and subsequently to PAH, due to the reversed or bidirectional blood flow through the defect [40,41]. According to the ESC and UK commissioning guidelines, Sildenafil is recommended as first line treatment in those patients to the patients in WHO FC III [42]. Similarly, sildenafil is regarded as standard therapy in the American Heart guidelines along with caution over the use of excessive dose (see below) [43]. Improvements in haemodynamic parameters and the increase in exercise capacity has been observed when a combination of Sildenafil and Bosentan was used on patients with Eisenmenger Syndrome [44]. Currently, however, there is still little evidence of the role of dual therapy in such patients, the effect of drug-drug interaction and any evidence of long term survival benefit in the paediatric population with the use of long-term PDE5 inhibitor therapy.

3.4. Lymphatic Malformations in Infants and Children

Sildenafil in the treatment of lymphatic malformations represents a new therapeutic avenue, although this indication needs further studies. After 20 weeks of therapy, one patient who had obstructive sleep apnoea, airway occlusion and the right ear canal infiltrated by a lymphatic malformation, showed improved symptomatology. Additionally, symptoms improved in 6/7 patients treated for this condition, suggesting a potential significant efficacy. There were no serious adverse effects in any of the patients and none of them had to stop their treatment [45].

4. Other Causes of Pulmonary Arterial Hypertension

There have also been a variety of other causes of PAH where children have been treated effectively with Sildenafil. For the patients who experienced high PVR after heart transplant, Sildenafil treatment improved the right ventricular dysfunction and decreased PVR [46]. This is a complex scenario, and relates to the multifactorial cause of PAH in such patients, from the pulmonary complications of transplantation, anti-rejection medication, increased systemic vascular resistance and also reduced ventricular function. Currently, it is not clear exactly how Sildenafil interacts in all of these different areas and additional studies are consequently needed.

Following the Fontan operation, for children and adolescents with functionally univentricular hearts, some patients have decreased pulmonary vascular compliance. In the absence of true PAH, but PVR is increased, Sildenafil or Bosentan therapy administered before and after Fontan surgery, has appeared to benefit such patients. This is now standard therapy both early on in intensive care, but also later in the “failing Fontan” period [47,48].
Five children who underwent haematopoietic stem cell transplant developed PH at a median of 2.5 months post-transplant. One of the children (the only one who survived) received Sildenafil therapy for 11 months, and was off oxygen and doing well after two years from the transplant. Although is an isolated case, this could open the door for Sildenafil use in many more conditions and underlines the importance of further investigations on the subject [49].

5. Dosage

Due to the increasing variety of pathologies in which Sildenafil is being used, and to the high number of comorbidities that are found in some of the paediatric patients, a unique dose regimen is almost impossible to establish, often leaving this matter to the judgment of the paediatric cardiologist. However, the approved and recommended dose regimen for oral administration varies according to body weight. In recent studies (STARTS 1 and 2), children were randomized in 4 dose groups of Sildenafil (low, medium, high and placebo) and comparison was made for survival between these groups. In total, a death rate of 16% was found, while the low dose category had the lowest percentage of deaths, at 9%. The medium category was found to have a death rate of 16%, and the high dose group had the highest mortality, as 22% of the patients died, who were treated with a high dose. Interestingly, regardless of the up-titrations that were conducted in the low dose group, the number of deaths in this group was found to be far less than the other groups [16].

Therefore, all patients over 1 year and under 20 kg should receive 10 mg of Sildenafil, three times a day. Even though it might be expected that older children should receive a higher dose, there have been concerns from the US that there was an excess mortality in children receiving high dose Sildenafil for PH [50]. As a result, the recommended dosage remains at a maximum administrated low dose, of 10 mg Sildenafil, three times daily. At this dose regimen, children did not show any significant improvements in haemodynamics or in exercise capacity and did not ameliorate their WHO FC, however a lower number of deaths is observed, compared to higher dosages [30].

6. Contraindications for Using Sildenafil in Infants and Children

Sildenafil cannot be used in severe cases of hypotension because of its vasodilatory effect. Its use is also contraindicated in left ventricle outflow obstruction, in PAH associated with sickle cell anaemia, as well as in pulmonary veno-occlusive disease. Due to the relative potency of Sildenafil on PDE6, it also cannot be indicated in ischaemic optic neuropathy and in hereditary degenerative retinal disorders [51]. Although it is not the topic of this paper, there are other PDE5i which can be used in situations where there is not a known class effect of contraindications. Tadalafil is now a standard therapy, with the advantage of daily use [1]. There is now good knowledge base for its use in children with few complications [52]. Overall however, the PDE5i have a good track record for their safety and efficacy as a group [53].

7. Interaction with Other Drugs Used in the Treatment of Pulmonary Arterial Hypertension

Treatment of PAH in infants and children represents a real challenge and sometimes requires a combination of drugs in order to improve patient outcomes. Regardless of the aetiology of PAH, WHO FC and clinical parameters showed improvement after treating the patients with Sildenafil and Bosentan [54]. However, when treating a patient with more than one drug, interactions may occur and can be a significantly and negatively affect the clinical outcome, rendering the risk of inefficacy or toxicity of the compound.

Negative interactions have not yet been established when combined therapy of the newer endothelin receptor antagonist Macitentan and Sildenafil was used to treat PAH in adults or paediatric patients [55]. The first breakthrough in treating PAH came with the discovery of Epoprostenol, an intravenously administrated prostacyclin analogue. Both in idiopathic PAH and that associated with congenital heart disease, Epoprostenol showed favourable results, improving survival, as well as reducing their symptoms [56–60]. Although its results are very promising, long-term treatment
is possible only in well-funded centres, because of the high cost and also because it can only be
administrated with supervision from a specialist. Therefore, in combination with IV treatment with
Epoprostenol, Sildenafil offers improved outcome to patients [60].

8. Morbidity and Mortality

To this date, the effect of Sildenafil on the mortality of infants and children with PAH is not clear
and further studies are still needed. After an average treatment duration of 4–12 months, the known
morbidity rate today is still between 5–30%. An insufficient number of studies have been conducted
for a clear rate to be determined, but many studies have contributed to a more accurate image of how
Sildenafil can be used as a potential therapy, in order to turn the risk and benefit balance in favour of
the paediatric patient [51].

9. Discussion

The PDE5 inhibitor Sildenafil is a valuable pharmacotherapy that can be used to treat children
and infants with PAH, both in monotherapy and combined therapy, as well as for additional related
diseases. Nowadays, Sildenafil is approved in Europe for the treatment of PAH in children aged
1–17 years, although with some caution required. The problematic matter of researching new drugs
on children is one of the main limitations for the use of Sildenafil, because without proper RCTs
being performed, researchers and clinicians cannot be fully aware of the detailed treatment effects or
consequent side effects. So far, the use of Sildenafil in the treatment of PAH in infants and children
has shown potential benefits and improved patient outcomes. One of the most pressing questions
that remains is at what dosage regimen patients can fully benefit from its favourable effects with the
minimum possible adverse reactions. As previously mentioned, frequency and severity of adverse
effects appear more often at higher doses (20 mg, 40 mg or 80 mg) of Sildenafil and are correlated with
higher mortality. At the opposite pole, the administration of low doses (10 mg) were less effective,
but have a much lower mortality risk.

Aside from the common aetiology, PAH as a result of cardiovascular surgery and haematological
disorders has been alleviated with the use of Sildenafil. Although the haemodynamic and
morphological aspects of cardiac transplantation and univentricular heart surgery have been subjected
to statistical analyses, in order to assess the efficacy of the PDE5 inhibitor, the data on stem cells
transplant remains scarce. The only existing information is from a study with a small group of five
children, of whom, the survival of one patient was attributed to the Sildenafil administration. Other
indications, such as in PPHN, BPD, CDH and Eisenmenger’s syndrome, have also had positive
outcomes of Sildenafil therapy, through the improvement of cardiorespiratory physiology, but the
variation in results among paediatric departments renders the need for further evaluation. Additionally,
the reports on lymphatic reductions also require further analysis, due to the reduced number of patients
in recently conducted studies.

In all cases, it is quintessential that the selection and monitoring of patients has to be thorough,
and that every aspect should be evaluated to establish clear criteria of Sildenafil administration, as well
as evidence-based data regarding dosage, in order to accomplish the best possible outcome.

10. Conclusions

It can be clearly seen that Sildenafil has been proven as a significant potential therapy which can
provide beneficial effects in contributing to the improvement of a large variety of conditions. However,
the currently available evidence-based data has inconsistent data, inconclusive pharmacological
evidence and a lack of exact protocols in different aetiologies of PAH, still create an obstacle for
the assessment of the role of Sildenafil, in spite of the recent advances that appear to demonstrate
its effectiveness. The potential of Sildenafil alone, and also in combination with other current
PAH therapies, requires additional exploration in order to find the correct treatment strategy for
the challenging paediatric pathology that is PH. Further research is needed to conclude the ideal
posology of Sildenafil and to establish its place in the future developments and therapies in the field of paediatric cardiology.

**Acknowledgments:** Robert Tulloh is supported by the NIHR Biomedical Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

**Author Contributions:** Both L.S. and R.T. contributed to the design, drafts and finished paper.

**Conflicts of Interest:** Robert Tulloh has received honoraria and lecture fees from Pfizer, Encysive, Bayer, Actelion and GSK.

**References**

1. Galie, N.; Humbert, M.; Vachiery, J.L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Vonk Noordegraaf, A.; Beghetti, M.; et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur. Heart J.* 2016, 37, 67–119. [PubMed]
2. Hoepur, M.M. Definition, classification, and epidemiology of pulmonary arterial hypertension. *Semin. Respir. Crit. Care Med.* 2009, 30, 369–375. [CrossRef] [PubMed]
3. Wardle, A.J.; Tulloh, R.M. Paediatric pulmonary hypertension and sildenafil: Current practice and controversies. *Arch. Dis. Child. Educ. Pract. Ed.* 2013, 98, 141–147. [CrossRef] [PubMed]
4. Tulloh, R. Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension. *Paediatr. Drugs* 2009, 11, 115–128. [CrossRef] [PubMed]
5. Simonneau, G.; Gatzoulis, M.A.; Adatia, I.; Celermajer, D.; Denton, C.; Ghofrani, A.; Gomez Sanchez, M.A.; Krishna Kumar, R.; Landzberg, M.; Machado, R.F.; et al. Updated clinical classification of pulmonary hypertension. *J. Am. Coll. Cardiol.* 2013, 62, D34–D41. [CrossRef] [PubMed]
6. Iacobazzi, D.; Suleiman, M.S.; Ghorbel, M.; George, S.J.; Caputo, M.; Tulloh, R.M. Cellular and molecular basis of RV hypertrophy in congenital heart disease. *Heart* 2016, 102, 12–17. [CrossRef] [PubMed]
7. Center for Drug Evaluation and Research. Nda 020895 Viagra® (Sildenafil Citrate) Tablets: Clinical Pharmacology/Biopharmaceutics Review; MDOHaHS; US Food and Drug Administration: Rockville, MD, USA, 1998.
8. Hemnes, A.R.; Champion, H.C. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. *Expert Rev. Cardiovasc. Ther.* 2006, 4, 293–300. [CrossRef] [PubMed]
9. Ghofrani, H.A.; Osterloh, I.H.; Grimminger, F. Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. *Nat. Rev. Drug Discov.* 2006, 5, 689–702. [CrossRef] [PubMed]
10. Pfeifer, A.; Ruth, P.; Dostmann, W.; Saubier, M.; Klatt, P.; Hofmann, F. Structure and function of cGMP-dependent protein kinases. *Rev. Physiol. Biochem. Pharmacol.* 1999, 135, 105–149. [PubMed]
11. Lucas, K.A.; Pitari, G.M.; Kazerounian, S.; Ruiz-Stewart, I.; Park, J.; Schulz, S.; Chepenik, K.P.; Waldman, S.A. Guanylyl cyclases and signaling by cyclic GMP. *Pharmacol. Rev.* 2000, 52, 375–414. [PubMed]
12. Sun, X.Z.; Li, Z.F.; Liu, Y.; Fang, P.; Li, M.X. Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. *Clin. Exp. Pharmacol. Physiol.* 2010, 37, 362–367. [CrossRef] [PubMed]
13. Broughton, B.R.; Walker, B.R.; Resta, T.C. Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2008, 294, L797–L806. [CrossRef] [PubMed]
14. Nagendran, J.; Archer, S.L.; Soliman, D.; Guratu, V.; Moudgil, R.; Haromy, A.; St Aubin, C.; Webster, L.; Rebejka, I.M.; Ross, D.B.; et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. *Circulation* 2007, 116, 238–248. [CrossRef] [PubMed]
15. Corbin, J.D.; Francis, S.H. Cyclic GMP phosphodiesterase-5: Target of sildenafil. *J. Biol. Chem.* 1999, 274, 13729–13732. [CrossRef] [PubMed]
16. Barst, R.J.; Ivy, D.D.; Gaitan, G.; Szatmari, A.; Rudzinski, A.; Garcia, A.E.; Sastry, B.K.; Pulido, T.; Layton, G.R.; Serdarevic-Pehar, M.; et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. *Circulation* 2012, 125, 324–334. [CrossRef] [PubMed]

17. Herbert, S.; Gin-Sing, W.; Howard, L.; Tulloh, R.M. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. *Heart Lung Circ.* 2017. [CrossRef] [PubMed]

18. Carls, A.; Winter, J.; Enderle, Y.; Burhenne, J.; Gorenflo, M.; Haefeli, W.E. Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: Two case reports. *J. Med. Case Rep.* 2014, 8, 171. [CrossRef] [PubMed]

19. Bialkowski, A.; Moenkemeyer, F.; Patel, N. Intravenous sildenafil in the management of pulmonary hypertension associated with congenital diaphragmatic hernia. *Eur. J. Pediatr. Surg.* 2015, 25, 171–176. [CrossRef] [PubMed]

20. Ahsman, M.J.; Witjes, B.C.; Wildschut, E.D.; Sluiter, I.; Vuito, A.G.; Tibboel, D.; Mathot, R.A. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. *Arch. Dis. Child. Fetal Neonatal Ed.* 2010, 95, F109–F114. [CrossRef] [PubMed]

21. Nichols, D.J.; Muirhead, G.J.; Harness, J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. *Br. J. Clin. Pharmacol.* 2002, 53, 5S–12S. [CrossRef] [PubMed]

22. Lacroix, D.; Sonnier, M.; Moncion, A.; Cheron, G.; Cresteil, T. Expression of CYP3A in the human liver—Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. *Eur. J. Biochem. FEBS* 1997, 247, 625–634. [CrossRef]

23. Muirhead, G.J.; Rance, D.J.; Walker, D.K.; Wastall, P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. *Br. J. Clin. Pharmacol.* 2002, 53, 13S–20S. [CrossRef] [PubMed]

24. Mukherjee, A.; Dombi, T.; Wittke, B.; Lalonde, R. Population pharmacokinetics of sildenafil in term neonates: Evidence of rapid maturation of metabolic clearance in the early postnatal period. *Clin. Pharmacol. Ther.* 2009, 85, 56–63. [CrossRef] [PubMed]

25. Muirhead, G.J.; Wilner, K.; Colburn, W.; Haug-Pihale, G.; Rouviex, B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. *Br. J. Clin. Pharmacol.* 2002, 53, 21S–30S. [CrossRef] [PubMed]

26. Koukouritaki, S.B.; Manro, J.R.; Marsh, S.A.; Stevens, J.C.; Rettie, A.E.; McCarver, D.G.; Hines, R.N. Developmental expression of human hepatic CYP2C9 and CYP2C19. *J. Pharmacol. Exp. Ther.* 2004, 308, 965–974. [CrossRef] [PubMed]

27. Samiee-Zafarghandy, S.; Smith, P.B.; Van Den Anker, J.N. Safety of sildenafil in infants. *Pediatr. Crit. Care Med.* 2014, 15, 362–368. [CrossRef] [PubMed]

28. Samiee-Zafarghandy, S.; Van Den Anker, J.N.; Laughon, M.M.; Clark, R.H.; Smith, P.B.; Hornik, C.P. Sildenafil and retinopathy of prematurity risk in very low birth weight infants. *J. Perinatol.* 2016, 36, 137–140. [CrossRef] [PubMed]

29. Azzouni, F.; Abu Samra, K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. *J. Sex. Med.* 2011, 8, 2894–2903. [PubMed]

30. Barst, R.J.; Beghetti, M.; Pulido, T.; Layton, G.; Konourina, I.; Zhang, M.; Ivy, D.D.; STARTS-investigators. STARTS-2: Long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. *Circulation* 2014, 129, 1914–1923. [PubMed]

31. Shah, P.S.; Ohlsson, A. Sildenafil for pulmonary hypertension in neonates. *Cochrane Database Syst. Rev.* 2011, CD005494.

32. Steinhorn, R.H.; Kinsella, J.P.; Pierce, C.; Butrous, G.; Dilleen, M.; Oakes, M.; Wessel, D.L. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. *J. Pediatr.* 2009, 155, 841–847. [CrossRef] [PubMed]

33. Nair, J.; Lakshminrusimha, S. Update on PPHN: Mechanisms and treatment. *Semin. Perinatol.* 2014, 38, 78–91. [CrossRef] [PubMed]

34. Greenough, A. Long-term pulmonary outcome in the preterm infant. *Neonatology* 2008, 93, 324–327. [CrossRef] [PubMed]
35. Khemani, E.; Mcelhinney, D.B.; Rhein, L.; Andrade, O.; Lacro, R.V.; Thomas, K.C.; Muellen, M.P. Pulmonary artery hypertension in premature infants with bronchopulmonary dysplasia: Clinical features and outcomes in the surfactant era. *Pediatrics* 2007, 120, 1260–1269. [CrossRef] [PubMed]
36. An, H.S.; Bae, E.J.; Kim, G.B.; Kwon, B.S.; Beak, J.S.; Kim, E.K.; Kim, H.S.; Choi, J.H.; Noh, C.I.; et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. *Korean Circ. J.* 2010, 40, 131–136. [CrossRef] [PubMed]
37. Mourani, P.M.; Sontag, M.K.; Ivy, D.D.; Abman, S.H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. *J. Pediatr.* 2009, 154, 379–384. [CrossRef] [PubMed]
38. Nyp, M.; Sandritter, T.; Poppinga, N.; Simon, C.; Truong, W.E. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: Any benefits? *J. Perinatol.* 2012, 32, 64–69. [CrossRef] [PubMed]
39. Wardle, A.J.; Wardle, R.; Luyt, K.; Tulloh, R. The utility of sildenafil in pulmonary hypertension: A focus on bronchopulmonary dysplasia. *Arch. Dis. Child.* 2013, 98, 613–617. [CrossRef] [PubMed]
40. Wood, P. The eisenmenger syndrome or pulmonary hypertension with reversed central shunt. *Br. Med. J.* 1958, 2, 701–709. [CrossRef] [PubMed]
41. Bradford, R.; Tulloh, R. Diagnosis and Management of Pulmonary hypertension in adult congenital heart disease. *Br. J. Cardiac. Nurs.* 2008, 3, 138–145. [CrossRef]
42. Baumgartner, H.; Bonhoeffer, P.; De Groot, N.M.; de Haan, F.; Deanfield, J.E.; Galie, N.; Gatzoulis, M.A.; Gohlke-Baerwolf, C.; Kaemmerer, H.; Künler, P.; et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur. Heart J.* 2010, 31, 2915–2957. [CrossRef] [PubMed]
43. Abman, S.H.; Hansmann, G.; Archer, S.L.; Ivy, D.D.; Adatia, I.; Chung, W.K.; Hanna, B.D.; Rosenzweig, E.B.; Raj, J.U.; Cornfield, D.; et al. Pediatric Pulmonary Hypertension: Guidelines from the American Heart Association and American Thoracic Society. *Circulation* 2015, 132, 2037–2099. [CrossRef] [PubMed]
44. D’Alto, M.; Romeo, E.; Argiento, P.; Sarubbi, B.; Santoro, G.; Grimaldi, N.; Correra, A.; Scognamiglio, G.; Russo, M.G.; Calabro, R. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. *Int. J. Cardiol.* 2012, 155, 378–382. [CrossRef] [PubMed]
45. Danial, C.; Tichy, A.L.; Tariq, U.; Swetman, G.L.; Khuu, P.; Leung, T.H.; Benjamin, L.; Teng, J.; Vasanawala, S.S.; Lane, A.T. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. *J. Am. Acad. Dermatol.* 2014, 70, 1050–1057. [CrossRef] [PubMed]
46. Singh, R.K.; Richmond, M.E.; Zuckerman, W.A.; Lee, T.M.; Giblin, T.B.; Rodriguez, R.; Chen, J.M.; Addonizio, L.J. The use of oral sildenafil for management of right ventricular dysfunction after pediatric heart transplantation. *Am. J. Transplant.* 2014, 14, 453–458. [CrossRef] [PubMed]
47. Ciliberti, P.; Schulze-Neick, I.; Giardini, A. Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: Focus on phosphodiesterase inhibitors. *Future Cardiol.* 2012, 8, 271–284. [CrossRef] [PubMed]
48. Van De Bruaene, A.; De Gercke, A.; Claessen, G.; De Meester, P.; Devroe, S.; Gillijns, H.; Bogaert, J.; Claes, P.; Heidbuchel, H.; Gewillig, M.; et al. Sildenafil improves exercise hemodynamics in Fontan patients. *Circ. Cardiovasc. Imaging* 2014, 7, 265–273. [CrossRef] [PubMed]
49. Jodele, S.; Hirsch, R.; Laskin, B.; Davies, S.; Witte, D.; Chima, R. Pulmonary Arterial Hypertension in Pediatric Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. *Biol. Blood Marrow Transplant.* 2012. [CrossRef]
50. US Food and Drug Administration. FDA Drug Safety Communication: FDA Recommends Against Use of Retinoic Acid for Children with Pulmonary Hypertension; US Food and Drug Administration: Silver Spring, MD, USA, 2012.
51. Wardle, A.J.; Connolly, G.M.; Stonier, T.; Tulloh, R. Sildenafil in bronchopulmonary dysplasia: Safe to use? *Arch. Dis. Child. Fetal Neonatal Ed.* 2015, 100, F369. [CrossRef] [PubMed]
52. Shiva, A.; Shiran, M.; Rafati, M.; Zanami, H.; Babazadeh, K.; Saeedi, M.; Ala, S. Oral Tadalafil in Children with Pulmonary Arterial Hypertension. *Drug Res.* 2016, 66, 7–10. [CrossRef] [PubMed]
53. Unebu, C.; Noje, C.; Coulson, J.D.; Segal, J.B.; Romer, L. Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors. *Pediatrics* 2017, 139, e20161450. [CrossRef] [PubMed]
54. Dardi, F.; Manes, A.; Palazzini, M.; Bachetti, C.; Mazzanti, G.; Rinaldi, A.; Albini, A.; Gotti, E.; Monti, E.; Bacchi Reggiani, M.L.; et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: Real-world insights. *Eur. Respir. J.* 2015, 46, 414–421. [CrossRef] [PubMed]
55. Sidharta, P.N.; Van Giersbergen, P.L.; Wolzt, M.; Dingemanse, J. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. *Br. J. Clin. Pharmacol.* 2014, 78, 1035–1042. [CrossRef] [PubMed]

56. Barst, R.J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. *Chest* 1986, 89, 497–503. [CrossRef] [PubMed]

57. Ivy, D.D.; Rosenzweig, E.B.; Lemarie, J.C.; Brand, M.; Rosenberg, D.; Barst, R.J. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. *Am. J. Cardiol.* 2010, 106, 1332–1338. [CrossRef] [PubMed]

58. Lammers, A.E.; Hislop, A.A.; Flynn, Y.; Haworth, S.G. Epoprostenol treatment in children with severe pulmonary hypertension. *Heart* 2007, 93, 739–743. [CrossRef] [PubMed]

59. Rosenzweig, E.B.; Kerstein, D.; Barst, R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. *Circulation* 1999, 99, 1858–1865. [CrossRef] [PubMed]

60. Melnick, L.; Barst, R.J.; Rowan, C.A.; Kerstein, D.; Rosenzweig, E.B. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. *Am. J. Cardiol.* 2010, 105, 1485–1489. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).